文献速递前列腺癌

男性胚系BRCA突变携带者:精准肿瘤学的成熟时机?

Germline BRCA mutation in male carriers-ripe for precision oncology?
PubMed 文献 · Prostate Cancer Prostatic Dis · 2017-12-14

本文通过Pubmed数据库检索并回顾重要文献,探讨胚系BRCA突变与前列腺癌风险及预后的关联。BRCA1/2突变分别使前列腺癌风险增加至多4.5倍和8.3倍,BRCA2突变与高分级疾病、转移性去势抵抗进展及5年癌症特异性生存率50%至60%相关。结论认为需更深入分析BRCA突变在前列腺癌自然史中的病因学作用,并关注携带者的筛查与化学预防研究。

要点

  • BRCA1/2突变分别使前列腺癌风险增加至多4.5倍和8.3倍。
  • BRCA2突变与高分级疾病、转移性去势抵抗进展及5年癌症特异性生存率50%至60%相关。
  • 需提高对BRCA突变作为前列腺癌风险标志物的筛查意识,并探索携带者的结构化筛查程序。

核心结论

  • 尽管DNA修复基因研究不断增多,仍需更深入分析以理解胚系BRCA突变在前列腺癌自然史中的病因学作用。
  • 需要提高对该前列腺癌风险标志物的筛查意识,并有机会为BRCA突变携带者制定结构化前列腺癌筛查程序。
  • 需进一步研究以确定该高风险亚组的潜在化学预防策略。

研究设计与样本

  • 通过Pubmed数据库检索并回顾重要文章的参考文献列表,以捕获探讨BRCA突变与前列腺癌风险及预后关联的论文,检索截至2017年5月并按相关性和发表类型筛选。

主要发现

  • BRCA1/2突变分别使前列腺癌风险增加至多4.5倍和8.3倍。
  • BRCA2突变与高分级疾病风险增加、进展为转移性去势抵抗性疾病相关,5年癌症特异性生存率为50%至60%。

临床怎么用

  • 原文提出需要提高对BRCA突变作为前列腺癌风险标志物的筛查意识,并有机会为BRCA突变携带者制定结构化前列腺癌筛查程序。
  • 原文提出需进一步研究以确定该高风险亚组的潜在化学预防策略。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Prostate cancer (PC) is one of the known heritable cancers with individual variations attributed to genetic factors. BRCA1 and BRCA2 are tumour suppressor genes with crucial roles in repairing DNA and thereby maintaining genomic integrity. Germline BRCA mutations predispose to multiple familial tumour types including PC. METHODS: We performed a Pubmed database search along with review of reference lists from prominent articles to capture papers exploring the association between BRCA mtuations and prostate cancer risk and prognosis. Articles were retrieved until May 2017 and filtered for relevance, and publication type. RESULTS: We explored familial PC genetics; discussed the discovery and magnitude of the association between BRCA mutations and PC risk and outcome; examined implications of factoring BRCA mutations into PC screening; and discussed the rationale for chemoprevention in this high-risk population. We confirmed that BRCA1/2 mutations confer an up to 4.5-fold and 8.3-fold increased risk of PC, respectively. BRCA2 mutations are associated with an increased risk of high-grade disease, progression to metastatic castration-resistant disease, and 5-year cancer-specific survival rates of 50 to 60%. CONCLUSION: Despite the growing body of research on DNA repair genes, deeper analysis is needed to understand the aetiological role of germline BRCA mutations in the natural history of PC. There is a need for awareness to screen for this marker of PC risk. There is similarly an opportunity for structured PC screening programs for BRCA mutation carriers. Finally, further research is required to identify potential chemopreventive strategies for this high-risk subgroup.

来源:Prostate Cancer Prostatic Dis,查看原文。版权归原作者所有。

引用

  1. Leão RRN, Price AJ, James Hamilton R, et al. Germline BRCA mutation in male carriers-ripe for precision oncology? Prostate Cancer Prostatic Dis. 2017. PMID: 29242595. doi:10.1038/s41391-017-0018-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。